M
Marco Pieroni
Researcher at University of Parma
Publications - 60
Citations - 1797
Marco Pieroni is an academic researcher from University of Parma. The author has contributed to research in topics: Mycobacterium tuberculosis & Efflux. The author has an hindex of 20, co-authored 56 publications receiving 1235 citations. Previous affiliations of Marco Pieroni include University of Illinois at Chicago & University of Perugia.
Papers
More filters
Journal ArticleDOI
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke,Marco Pieroni,Tilmann Weber,Mark Brönstrup,Peter Hammann,Ludovic Halby,Paola B. Arimondo,Philippe Glaser,Bertrand Aigle,Helge B. Bode,Helge B. Bode,Rui Moreira,Yanyan Li,Andriy Luzhetskyy,Marnix H. Medema,Jean-Luc Pernodet,Marc Stadler,José R. Tormo,Olga Genilloud,Andrew W. Truman,Kira J. Weissman,Eriko Takano,Stefano Sabatini,Evi Stegmann,Heike Brötz-Oesterhelt,Wolfgang Wohlleben,Myriam Seemann,Martin Empting,Anna K. H. Hirsch,Brigitta Loretz,Claus-Michael Lehr,Alexander Titz,Jennifer Herrmann,Timo Jaeger,Silke Alt,Thomas Hesterkamp,Mathias Winterhalter,Andrea Schiefer,Kenneth Pfarr,Achim Hoerauf,Heather Graz,Michael Graz,Mika Lindvall,Savithri Ramurthy,Anders Karlén,Maarten van Dongen,Hrvoje Petković,Andreas Keller,Frédéric Peyrane,Stefano Donadio,Laurent Fraisse,Laura J. V. Piddock,Ian H. Gilbert,Heinz E. Moser,Rolf Müller +54 more
TL;DR: In this paper, the authors present a strategic blueprint to substantially improve our ability to discover and develop new antibiotics, and propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding.
Journal ArticleDOI
Indoleamides are active against drug-resistant Mycobacterium tuberculosis
Shichun Lun,Haidan Guo,Oluseye K. Onajole,Marco Pieroni,Hendra Gunosewoyo,Gang Chen,Suresh K. Tipparaju,Nicole C. Ammerman,Alan P. Kozikowski,William R. Bishai +9 more
TL;DR: Lead compounds, the indoleamides, with potent activity against both drug-susceptible and drug-resistant strains of M. tuberculosis by targeting the mycolic acid transporter MmpL3 are described, indicating great potential for translational developments of this structure class for the treatment of drug- resistant tuberculosis.
Journal ArticleDOI
Preliminary Structure–Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
Oluseye K. Onajole,Marco Pieroni,Marco Pieroni,Suresh K. Tipparaju,Shichun Lun,Jozef Stec,Jozef Stec,Gang Chen,Hendra Gunosewoyo,Haidan Guo,Nicole C. Ammerman,William R. Bishai,William R. Bishai,Alan P. Kozikowski +13 more
TL;DR: Three molecules possessing an exceptional activity in the low nanomolar range against actively replicating Mycobacterium tuberculosis are identified, with minimum inhibitory concentration (MIC) values lower than those of the most prominent antitubercular agents currently in use.
Journal ArticleDOI
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
Jialin Mao,Hai Yuan,Yuehong Wang,Baojie Wan,Marco Pieroni,Qingqing Huang,Richard B. van Breemen,Alan P. Kozikowski,Scott G. Franzblau +8 more
TL;DR: Compound 9d with an alkene linker was found to be both more metabolically stable and more potent than compound 3, with a minimum inhibitory concentration of 0.2 microM against replicating and nonreplicating Mycobaterium tuberculosis.
Journal ArticleDOI
In Pursuit of Natural Product Leads: Synthesis and Biological Evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4-carboxylic acid (A-33853) and Its Analogues: Discovery of N-(2-Benzoxazol-2-ylphenyl)benzamides as Novel Antileishmanial Chemotypes
Suresh K. Tipparaju,Sipak Joyasawal,Marco Pieroni,Marcel Kaiser,Reto Brun,Alan P. Kozikowski +5 more
TL;DR: The first synthesis and biological evaluation of antibiotic 31 (A-33853) and its analogues are reported and revealed 31 to be 3-fold more active than miltefosine, a known antileishmanial drug.